N umerous recent studies demonstrated that nitric oxide (NO) has a variety of antiatherogenic actions on the vascular system, such as inhibitory effects on the growth of vascular smooth muscle cells, platelet aggregation, and leukocyte adhesion to the endothelium. It is likely that the failure of NO release causes significant changes in vascular homeostasis and promotes atherogenesis. 1 The vascular endothelium in atherosclerosis fails to release NO, in contrast to that in the normal vascular bed. 2 In vivo studies have revealed that arginine supplementation improved NO release from the endothelium both in hypercholesterolemic animals and in humans. [3] [4] [5] Significant alleviation of the formation and progression of atherosclerosis by arginine supplementation has been reported. 6 These results suggest that the availability of arginine in the cytoplasm of endothelial cells is reduced in the state of hypercholesterolemia, and it is highly probable that an exogenous supply of arginine could ameliorate the impaired NO release and suppress atherogenesis.
Evidence has accumulated that oxidized LDL (OxLDL) or its lipid constituent, lysophosphatidylcholine (LPC), plays a critical role in atherogenesis. 7, 8 Immunohistochemical studies of atherosclerotic lesions have revealed the deposition of OxLDL, which is taken up by monocytes/macrophages. 9 LPC is formed in the process of oxidative modifications of LDL. It is a major deleterious component of OxLDL, constituting up to 40% of the total lipid content of OxLDL. LPC, like OxLDL, shows a special atherogenic capacity including the induction of growth/chemotactic factors, induction of leukocyte adhesion molecule, and inhibition of the NO release from endothelium. 8, 10, 11 To clarify the change of arginine availability, we focused on the relationships between arginine transport and NO production in endothelial cells treated with LPC. The arginine uptake in endothelial cells is mainly mediated by system y ϩ , a sodium-independent transport system of cationic amino acids. The 4 members of the system y ϩ transporter family identified to date are cationic amino acid transporters (CAT1, CAT2a, CAT2b, and CAT3). 12, 13 According to their different affinities to arginine, 3 of these transport systems (CAT1, CAT2b, and CAT3) are classified as high-affinity (K d Ϸ10 Ϫ4 mol/L) transporters, whereas CAT2a, an alternatively spliced isoform of CAT2b, is classified as a low-affinity (K d Ϸ10 Ϫ3 or more mol/L) transporter.
The present results revealed that (1) the decrease in NO production in endothelial cells treated with LPC was reversed by high dose of arginine; (2) arginine uptake of endothelial cells was mediated by the 2 pathways, high-and low-affinity arginine transport systems; and (3) LPC selectively inhibited the high-affinity system. Our findings unveil one of the molecular mechanisms underlying the in vivo observations that high-dose arginine attenuates atherogenesis by increasing endothelium-derived NO release.
Materials and Methods

Culture
Bovine aortic endothelial (BAE) cells were maintained in DMEM supplemented with 10% FCS, 100 U/mL of ampicillin, 0.1 mg/mL of streptomycin, and 250 ng/mL of amphotericin B (Fungizone; Gibco) at 37°C under humidified atmosphere containing 5% CO 2 . Cell viability was determined using the trypan blue exclusion assay and by measurement of the activity of lactate dehydrogenase leaked from dead cells into the culture medium using a lactate dehydrogenasecytotoxic test kit (Wako).
Preparation of LDL
Human plasma LDL (densityϭ1.019 to 1.063) was isolated by sequential ultracentrifugation, and oxidative modification of LDL was carried out with cupric ion in vitro, as described previously. 14 Oxidation was monitored by measuring the amount of thiobarbituric acid-reactive substances (Ϸ10 nmol malondialdehyde equivalent/mg protein in OxLDL). Agarose gel electrophoresis revealed an increase in electrophoretic mobility and minimal aggregation of OxLDL particles. Into a tube containing a 1:9 volume of 3.8% sodium citrate solution as an anticoagulant, peripheral venous blood was withdrawn from healthy volunteers who had not taken any drugs for at least 2 weeks. Platelet-rich plasma (PRP) and platelet-poor plasma were obtained as supernatants after centrifugation for 10 minutes at 160g and 1500g, respectively. 15 Two hundred microliters of PRP prewarmed at 37°C was set in an aggregometer (Heam Tracer 601; Niko Bioscience) with continuous stirring at 1000 rpm. Twenty microliters of the suspension of BAE cells, prepared as described above, was added to the PRP and incubated for 1 minute. Addition of endothelial cells (5ϫ10 4 
Bioassay of NO Release From BAE Cells
Measurement of Arginine Uptake by Endothelia of Intact Bovine Aortas
Bovine aortas freshly obtained from a local slaughterhouse were cut longitudinally and incubated at 37°C for 2 hours with HBS, 0.3% BSA with or without 100 mol/L LPC. The media were changed with HBS containing [ 3 H]arginine to allow the aortas to incorporate arginine for 3 minutes. After being washed with ice-cold HBS, the endothelia were scraped off with coverslips and lysed with 0.2 mol/L NaOH and 1% SDS. The radioactivity and protein concentration of the lysate were determined. The scraped cells were identified as vascular endothelial cells by the further culturing of the cells in parallel experiments.
cDNA Cloning of CAT1
cDNA libraries from human lung and brain constructed in the gt10 vector were screened by the standard plaque hybridization method as described. 13 The insert of a positive clone (hCAT1) was subcloned into pBluescript II SKϪ (Stratagene) to give pBShCAT1. It was confirmed by sequencing that hCAT1 covered the whole coding region of human CAT1 cDNA.
Transient Expression of CAT1 in COS-7 cells
The EcoRI fragment of hCAT1 was subcloned into a mammalian expression vector pME18S to give pMEhCAT1. COS-7 cells were maintained in DMEM supplemented with 10% FBS. The COS-7 cells to be transfected were seeded on 10-cm dishes the night before, to give 50% confluence at the time of transfection. The cells were transfected with 10 g of pMEhCAT1 or with the vector (for basal uptake) using LipofectAMINE (Life Technologies, Inc) according to the instructions of the manufacturer. Twenty-four hours later, the cells were transferred to 12-well plates and the medium was changed with arginine-free MEM. Twenty-four hours after this, the cells were used for the determination of arginine uptake.
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Northern Blotting
Poly(A) ϩ RNA (10 g per lane), prepared from BAE cells, was separated by formaldehyde/1.1% agarose gel electrophoresis and transferred to a nylon membrane (Gene Screen Plus; Du Pont). The membrane was hybridized with the probe, which was prepared by labeling the EcoRI fragment of pMEhCAT1 with [ 32 P]dCTP (110 TBq/mmol; Amersham). Blotting procedures were as described. 18 The blot was visualized for radioactivity with a BAS2000 image analyzer (Fujifilm Co Ltd).
Results
To measure the amount of NO released from BAE cells, we used a standard bioassay based on the antiaggregational effect of NO, as previously described. 16 PRP was used to analyze the reaction under conditions similar to those in vivo. ADP was chosen for initiating platelet aggregation, because it simultaneously activates endothelial cells to release NO. ADP induced platelet aggregation in PRP in a dose-dependent manner ( Figure 1A ). As expected, sodium nitroprusside, a NO donor, inhibited the ADP (10 Ϫ5 mol/L)-induced platelet aggregation in a dose-dependent manner ( Figure 1B) . Similarly, the addition of BAE cells to PRP also inhibited ADP-stimulated platelet aggregation ( Figure 1C ). The inhibitory effect of BAE cells was dependent on the number of BAE cells and was inhibited by L-nitroarginine-methylester (NAME), a NO synthase (NOS) inhibitor that has little effect on arginine transport ( Figure 1D) . 19 Although the inhibition by NAME was moderate, the reason may be that the serum contained about 0.1 mmol/L arginine, one tenth of the concentration of NAME used. Without addition of BAE cells, NAME did not affect platelet aggregation. Thus, this bioassay system is an appropriate method for the measurement of NO release from endothelial cells.
Using this assay system, we confirmed that LPC dosedependently inhibits NO release from BAE cells (Figure 2) . The inhibited NO release was restored by the addition of 10 mmol/L arginine, but not by 10 mmol/L lysine, which is also a dibasic amino acid but not a substrate of NOS ( Figure  3 ). In addition, the NO release from untreated BAE cells was not affected by the addition of 10 mmol/L arginine or lysine (data not shown). The findings also demonstrated that BAE cells treated with LPC required more extracellular arginine than the physiological concentration to produce an equivalent amount of NO as in the normal condition. These findings suggest that the arginine uptake by endothelial cells would be inhibited by the LPC treatment because the concentration of serum arginine is about 0.1 mmol/L, which is far higher than the K m value of NOS for arginine.
To test this hypothesis, we measured the uptake of extracellular arginine into BAE cells in the presence of 100 nmol/L of [ 3 H]arginine. As expected, the transport was significantly inhibited by the addition of LPC or OxLDL but not by PC or native LDL ( Figure 4A ). The inhibitory effect of LPC reached the maximum within 1 hour of incubation and continued for at least 5 hours ( Figures 4B  and 5A ). This inhibitory effect was dependent on the concentration of LPC ( Figure 5B ). In contrast to that of arginine, the transport of leucine, which is carried out by another transport system, was not inhibited even at the maximum dose of LPC ( Figure 5C ).
To exclude the possibility that these changes in arginine transport were due to nonspecific detergent-like effects of LPC, the viability of BAE cells was confirmed using the trypan blue exclusion assay and by measurement of the activity of lactate dehydrogenase released from dead BAE cells in the culture media. The results disclosed that BAE cells were still viable even in the presence of 100 mol/L LPC in our culture system. The concentration of LPC in the vessel wall of an atherosclerotic lesion, according to the report by Portman and Alexander, 20 was about 1 mmol/L, 10 times higher than the maximum concentration used in the present study. The detergent-like effects do not occur in vivo even at the highest concentration of LPC, probably because most of the LPC present was in a protein-bound form. In this sense, LPC was used in combination with 0.3% albumin as a carrier protein, as described previously. We examined whether the restoration of NO release by the administration of arginine at high concentrations was caused by the change in the activity of arginine transport. We analyzed the transport of arginine in the presence of extracellular arginine at various concentrations. Increase in the concentration of extracellular arginine facilitated the transport of arginine in a dose-dependent manner ( Figure 6A ). The addition of LPC reduced the transport particularly at low concentrations of extracellular arginine but not at the highest concentration (3 mmol/L), suggesting a decrease in the affinity of the transport system to arginine. The maximum activity of arginine transport in LPC-treated BAE cells was not significantly different from that in untreated BAE cells.
Analysis by the Eadie-Hoffstee plot ( Figure 6B ) confirmed that there are 2 components of arginine transport with different affinities to arginine in BAE cells, as reported previously. 23 The plot further revealed that the inhibition with LPC was highly selective to the high-affinity component of arginine transport, indicating that the restored activity at a high concentration of extracellular arginine was predominantly caused by the low-affinity arginine transporter that was relatively insensitive to LPC.
We confirmed the expression of CAT1, a ubiquitous and major high-affinity transporter, in the endothelial cells using Northern blot analysis ( Figure 7A ). We examined whether the activity of CAT1 was inhibited by LPC using COS-7 cells transfected with CAT1 cDNA. As expected, the activity of CAT1 was inhibited by LPC in a comparable dose of LPC, directly demonstrating the involvement of CAT1 in the LPC-mediated inhibition of high-affinity transport of arginine ( Figure 7B ).
Finally, we examined whether the effect of LPC on the arginine transport would be seen in intact blood vessels. Treatment of freshly isolated intact bovine aortas with comparable amounts of LPC from the luminal side significantly decreased activity of arginine transport in endothelial cells (Figure 8 ), suggesting that LPC inhibits arginine transporter not only in the cultured endothelial cells, but also in vivo in atherosclerotic lesions.
We also examined whether LPC affects the Ca 2ϩ transient in BAE cells induced by ADP stimulation in our system, because it is controversial between other reports. 24, 25 In the present study, LPC did not reveal significant change in the Ca 2ϩ transient ( Figure 9 ). The findings suggest that NO release can be impaired with the change in arginine transport but without the change in agonist-induced intracellular Ca 2ϩ transient.
Discussion
The findings in the present study revealed a novel mechanism of the impairment of the arginine-NO pathway in endothelial cells by atherogenic lipid. The failure of NO release by endothelial cells in the basal state and/or in response to various stimuli is thought to be a major change in atherosclerotic lesions. 2 Many reports indicate the amelioration of endothelial dysfunction and retardation in atherogenesis by in vivo arginine supplementation, 3-6,26 -29 suggesting that the amount of arginine available to NOS might be decreased in these endothelial cells.
Extracellular Arginine and NO Production
To investigate the potential mechanisms of the effect of LPC, we developed an assay system specifically to measure the amount of NO release from endothelial cells suspended in PRP. The advantage of this method is that the medium closely approximates in vivo conditions. Whereas other methods used for the measurement of NO were not sensitive enough, the method used in the present study permitted direct observation of the interaction between endothelial cells and platelets mediated by NO with enough sensitivity in real time to prevent the subtle changes of NO release from being overlooked. Experiments using this method confirmed the reduction of NO release from endothelial cells in the presence of LPC. Despite the existence of Ϸ0.1 mmol/L arginine in the medium, supplements of extracellular arginine (10 mmol/L) reversed the reduction, indicating that LPC possibly decreased the availability of extracellular arginine for NOS. In contrast, the NO release from the BAE cells not treated with LPC was not affected by high concentrations of arginine. These findings suggested that incorporation of arginine from extracellular space would not work well in the LPC-treated cells, in combination with the intracellular arginine supply system for NOS, because the extracellular concentration of L-arginine (about 0.1 mmol/L) is higher than the K m value of endothelial NOS. 23, 24 The total arginine transport activity was reduced. The reduction was caused by the decrease in the activity of the high-affinity transport system. This explains why the addition of excess amounts of arginine restores NO release in LPC-treated cells. With an increase in the extracellular arginine level, arginine can be carried by the lowaffinity arginine transporter rather than the high-affinity transporter. The K d value of high-affinity arginine transporter (about 0.1 mmol/L) was close to the concentration of arginine in normal plasma. Therefore, the change in the activity of the high-affinity arginine transporter markedly affected the total capacity of the arginine transport system in endothelial cells under physiological conditions. Indeed, Closs et al 30 reported that the uptake of arginine by CAT1, which mediates highaffinity transport, was several times higher than that by CAT2, which mediates the low-affinity transport of arginine, at physiological concentrations using an expression system in Xenopus oocytes.
Mechanism of Selective Inhibition of the High-Affinity Arginine Transporter
The detailed mechanisms of selective inhibition of the highaffinity arginine transporter are unclear (Figure 7 ). Closs et al 31 reported that CAT1 requires cationic amino acids on the trans side of the plasma membrane for its transporter activity, but CAT2 does not. Accordingly, if LPC reduces the intracellular arginine level, the activity of the high-affinity arginine transporter decreases. Because at normal physiological concentrations of arginine CAT1 is the predominant transport system in endothelial cells, this decrease results in the lowering of the intracellular arginine concentration and, in turn, a decrease in the arginine transport activity. Although its triggering mechanism is still unknown, this positive feedback loop may produce a deficiency of arginine in endothelial cells. Given that OxLDL readily evokes arginine deficiency in BAE cells in the absence of extracellular arginine, the existence of some mechanism for specifically reducing the available intracellular arginine is suggested. 32 LPC is assumed to inactivate the arginine transporter with translocation of the transporter from caveolae to some other portion, as observed in endothelial NOS. [33] [34] [35] Endothelial NOS reportedly localizes in the caveola, a specialized structure in the plasma membrane. . Disruption of the localization by a point mutation of endothelial NOS significantly decreased the activity, 34, 36, 37 suggesting that the microenvironment around caveolae is important in constitutive production of NO and that the arginine concentration in the cytoplasm might be heterogeneous and concentrated around caveolae. According to the recent report of McDonald et al, 35 CAT1 and endothelial NOS are colocalized in caveolae in endothelial cells. Therefore, a decrease in the concentration of arginine around arginine transporters results in a decrease in the activity of the arginine transporter, as described above, and further decreases the amount of arginine supplied to NOS complexed with CAT1.
Relationships to Other Proposed Mechanisms
Several investigators reported that G protein-mediated signal transduction was impaired by OxLDL and LPC. 38, 39 Because the response after transient Ca 2ϩ change induced by A23187 was preserved, the upstream mechanism of the transient Ca 2ϩ change in response to agonists has been focused on as the cause of the impaired NO release. 40 , 41 Inoue et al 24 reported that LPC inhibited bradykinin-induced Ca 2ϩ transients. The phenomenon observed seems to be a heterologous desensitization, because LPC itself induced Ca 2ϩ transients in endothelial cells. In contrast, in the present study, NO release was inhibited by LPC without any significant change in the intracellular Ca 2ϩ transient in response to ADP as analyzed with fluo-3 ( Figure 9 ). Shin et al 25 also reported that LPC inhibited NO release induced by ATP without decreasing the Ca 2ϩ transient of endothelial cells. These results suggest that the impairment of NO release can be induced solely by the reduction of arginine availability, although the Ca 2ϩ -dependent mechanism may also work under some conditions. Impairment of basal release of NO, which is independent of the intracellular Ca 2ϩ transient, may also be explained by the change of arginine availability. Arginine transport is also stimulated by the agonists of endothelial cells (Figure 10 ) such as bradykinin and ATP. 42 The process of receptormediated arginine transport may also be involved in the impairment of NO release.
It has been reported that interactions between arginine and glutamine change endothelial NO production and that arginine deficiency causes production of superoxide anions by neuronal NOS. 43 , 44 Durante et al 45 reported that the transport of cationic amino acid in vascular smooth muscle cells is inhibited in the short term but enhanced in the long term by the treatment of LPC. The enhancement of the transport was not observed in the present study; this may be because of the difference in the origin and the metabolism of the cells. They observed the change in the amount of mRNA for CAT1 and CAT2, but for the short-term effect of LPC, the change does not seem to correlate with the transport activity. Therefore, the inhibitory effect should occur at the protein level of the transporters. There may be a common mechanism reducing the activity of CAT in endothelial cells. Durante et al 45 also suggested that the polyamine metabolism might be important for the inhibition of NO production by inducible NOS in vascular smooth muscle cells. The inducible NOS requires much larger amounts of arginine (and various factors should modulate the arginine availability) than is the case with endothelial NOS. Thus, the relationships between arginine metabolism and NO production may be more complicated than the system used in the present study. Our present findings, however, are still compatible with previous reports on other factors. The inhibition of the high-affinity arginine transport seems to constitute, at least in part, the impairment of NO release by LPC in endothelial cells.
Therapeutic Possibilities
Evidence has accumulated that in vivo administration of arginine improves atherosclerosis by increasing NO release from endothelial cells. 6 The present results suggest the potential of the arginine transporter for the gene therapy of atherogenesis. Two types of high-affinity arginine transporter, CAT1 and CAT3, would be good transgene candidates.
